These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 24190981)

  • 1. Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma.
    Kadoch C; Li J; Wong VS; Chen L; Cha S; Munster P; Lowell CA; Shuman MA; Rubenstein JL
    Clin Cancer Res; 2014 Feb; 20(4):1029-41. PubMed ID: 24190981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement activation and rituximab distribution in CNS NHL--letter.
    Hofer S; Mengele K; Schmitt M; Pestalozzi B; Aebi S
    Clin Cancer Res; 2015 Jan; 21(2):490. PubMed ID: 25593346
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of primary central nervous system lymphoma with induction of complement-dependent cytotoxicity by intraventricular administration of autologous-serum-supplemented rituximab.
    Takami A; Hayashi T; Kita D; Nishimura R; Asakura H; Nakao S
    Cancer Sci; 2006 Jan; 97(1):80-3. PubMed ID: 16367925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Objective cerebrospinal fluid response to intraventricular rituximab in indolent CNS lymphoma.
    Strowd RE; Abuali IA; Grossman SA
    CNS Oncol; 2015; 4(3):131-5. PubMed ID: 25905905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab.
    Pels H; Schulz H; Manzke O; Hom E; Thall A; Engert A
    J Neurooncol; 2002 Sep; 59(3):213-6. PubMed ID: 12241117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma.
    Harjunpää A; Wiklund T; Collan J; Janes R; Rosenberg J; Lee D; Grillo-López A; Meri S
    Leuk Lymphoma; 2001 Aug; 42(4):731-8. PubMed ID: 11697503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma.
    Rubenstein JL; Li J; Chen L; Advani R; Drappatz J; Gerstner E; Batchelor T; Krouwer H; Hwang J; Auerback G; Kadoch C; Lowell C; Munster P; Cha S; Shuman MA; Damon LE
    Blood; 2013 Jan; 121(5):745-51. PubMed ID: 23197589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of central nervous system lymphoma in rats with intraventricular rituximab and serum.
    Miyake Y; Okoshi Y; Machino T; Chiba S
    Int J Hematol; 2010 Oct; 92(3):474-80. PubMed ID: 20820968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment.
    Rubenstein JL; Combs D; Rosenberg J; Levy A; McDermott M; Damon L; Ignoffo R; Aldape K; Shen A; Lee D; Grillo-Lopez A; Shuman MA
    Blood; 2003 Jan; 101(2):466-8. PubMed ID: 12393404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful use of intraventricular and intravenous rituximab therapy for refractory primary CNS lymphoma in a child.
    Akyuz C; Aydin GB; Cila A; Akalan N; Soylemezoglu F; Cengiz M; Yazici N; Buyukpamukcu M
    Leuk Lymphoma; 2007 Jun; 48(6):1253-5. PubMed ID: 17577799
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma.
    Rubenstein JL; Fridlyand J; Abrey L; Shen A; Karch J; Wang E; Issa S; Damon L; Prados M; McDermott M; O'Brien J; Haqq C; Shuman M
    J Clin Oncol; 2007 Apr; 25(11):1350-6. PubMed ID: 17312328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intra-CSF rituximab for lymhomatous meningitis.
    Chamberlain MC; Glantz MJ
    J Clin Oncol; 2007 Oct; 25(28):4508-9; author reply 4509-11. PubMed ID: 17906219
    [No Abstract]   [Full Text] [Related]  

  • 13. Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model.
    Wang SY; Veeramani S; Racila E; Cagley J; Fritzinger DC; Vogel CW; St John W; Weiner GJ
    Blood; 2009 Dec; 114(26):5322-30. PubMed ID: 19805620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with rituximab and temozolomide for recurrent and refractory primary central nervous system lymphoma.
    Murakami M; Fujimaki T; Asano S; Nakaguchi H; Yamada SM; Hoya K; Yamazaki K; Ishida Y; Matsuno A
    Yonsei Med J; 2011 Nov; 52(6):1031-4. PubMed ID: 22028172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab is associated with improved survival for aggressive B cell CNS lymphoma.
    Gregory G; Arumugaswamy A; Leung T; Chan KL; Abikhair M; Tam C; Bajel A; Cher L; Grigg A; Ritchie D; Opat S
    Neuro Oncol; 2013 Aug; 15(8):1068-73. PubMed ID: 23502429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study.
    Davies A; Merli F; Mihaljevic B; Siritanaratkul N; Solal-Céligny P; Barrett M; Berge C; Bittner B; Boehnke A; McIntyre C; Macdonald D
    Lancet Oncol; 2014 Mar; 15(3):343-52. PubMed ID: 24521993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
    Wong ET
    Neurology; 2005 Mar; 64(5):934; author reply 934. PubMed ID: 15753455
    [No Abstract]   [Full Text] [Related]  

  • 18. Rituximab monotherapy for patients with recurrent primary CNS lymphoma.
    Batchelor TT; Grossman SA; Mikkelsen T; Ye X; Desideri S; Lesser GJ
    Neurology; 2011 Mar; 76(10):929-30. PubMed ID: 21383331
    [No Abstract]   [Full Text] [Related]  

  • 19. CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group.
    Schmitz N; Zeynalova S; Glass B; Kaiser U; Cavallin-Stahl E; Wolf M; Haenel M; Loeffler M; Truemper L; Pfreundschuh M
    Ann Oncol; 2012 May; 23(5):1267-1273. PubMed ID: 21989328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of intrathecal rituximab in children with B cell lymphoid CD20+ malignancies: An international retrospective study.
    Ceppi F; Weitzman S; Woessmann W; Davies K; Lassaletta A; Reismüller B; Mellgren K; Uyttebroeck A; Maia I; Abdullah S; Miakova N; Glaser D; Cohn R; Abla O; Attarbaschi A; Alexander S
    Am J Hematol; 2016 May; 91(5):486-91. PubMed ID: 26872652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.